What’s Hot Today: InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), Navient Corporation (NASDAQ:NAVI), JetBlue Airways Corporation (NASDAQ:JBLU), Ohr Pharmaceutical, Inc. (NASDAQ:OHRP)

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) belongs to Healthcare sector. Its weekly performance is -16.00%. On last trading day company shares ended up $14.44. InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) distance from 50-day simple moving average (SMA50) is -0.13%. On July 06, InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) announced a one-month post-implant update for the third study patient and a six-month post-implant update for the second study patient in the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with complete acute spinal cord injury. In the time between implantation and the one-month post-injury assessment of the third study patient, the patient improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. The patient has regained sacral sensation with improved bladder function. Historically, fewer than 4% of patients with a high thoracic neurologic level of injury convert from AIS A to AIS B in the first month after injury.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) shares increased 4.33% in last trading session and ended the day at $14.21. MRNS return on assets is -44.50%. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) quarterly performance is 57.71%. On July 6, Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS announced that Jozef Gecz, Ph.D., Professor of Human Genetics at the Department of Pediatrics, University of Adelaide, published data in the June issue of Human Molecular Genetics, supporting the role for neurosteroids in the pathophysiology of PCDH19 female epilepsy. Marinus is currently conducting a Phase 2 clinical trial in PCDH19 with ganaxolone, a small molecule that is a synthetic analog of the endogenous neurosteroid allopregnanolone, and received orphan designation from the United States Food and Drug Administration for PCDH19 female epilepsy earlier this year.

Navient Corporation (NASDAQ:NAVI) belongs to Financial sector. Its net profit margin is 31.60% and weekly performance is -1.34%. On last trading day company shares ended up $18.36. Navient Corporation (NASDAQ:NAVI) distance from 50-day simple moving average (SMA50) is -3.80%. Navient Corp (NASDAQ:NAVI), a provider of financial products and services, on Monday said it expects it second-quarter core earnings of about $0.40 per share, and net earnings of about $0.47 per share. Analysts polled by Thomson Reuters currently expect the company to report earnings of $0.55 per share for the second quarter. Analysts’ estimates typically exclude one-time items.

JetBlue Airways Corporation (NASDAQ:JBLU) shares increased 1.24% in last trading session and ended the day at $21.99. JBLU Gross Margin is 55.30% and its return on assets is 6.80%. JetBlue Airways Corporation (NASDAQ:JBLU) quarterly performance is 10.78%. JetBlue Airways Corp (NASDAQ:JBLU) said Monday that its June traffic rose 8.8% from a year ago to 3.54 billion revenue passenger miles. JetBlue said its capacity in June increased 86% year-over-year to 4.15 billion available seat miles.

Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) shares increased 62.56% in last trading session and ended the day at $3.69. OHRP return on assets is -35.60%. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) quarterly performance is 35.66%. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), announced positive final results from a Phase II investigator sponsored clinical trial of OHR-102 (0.2% Squalamine lactate ophthalmic solution) in patients with macular edema secondary to branch (BRVO) and central retinal vein occlusion (CRVO). The results demonstrated that, following an initial 10 week combination therapy treatment period, patients who continued to receive a combination of topical OHR-102 BID plus Lucentis(R) achieved greater visual acuity gains than the control group who received Lucentis alone.

Leave a Reply

Your email address will not be published. Required fields are marked *